Our preliminary data that collagenase (MMP-1) expression in scleroderma (SSc) fibroblasts is inhibited even after stimulation with TNFalpha, IL-1 Beta and PMA is extremely relevant for the accumulation of collagen in this disease. Both rnRNA and protein are reduced in stimulated cells and that these phenomena are seen in the, lesion but not the non-lesion fibroblasts. We will focus on the phenotype of the scleroderma fibroblast in relation to the level and degree of collagenase inhibition with regard to transcriptional or translational control in SSc fibroblasts stimulated with TNF-alpha or PMA as compared to collagenase induction in normal fibroblasts, Our study of transcriptional regulation of MMP- 1 levels will investigate the level and function of AP- 1 complexes as these represent the predominant intersection of the signaling pathways of the different stimuli. We will quantitate the amount and activity of different Fos and Jun family members which have been identified in these complexes in extracts of basal and stimulated SSc and normal fibroblasts and determine their ability to bind to the two AP-1 sequences which are active in the MMP-1 promoter. We will also examine levels of the many other genes known to affect collagenase expression using DNA microarray analyses of mRNA from stimulated and unstimulated cultures of SSc and normal fibroblasts. Finally, we will address the relevancy of the observation that icIRAP is elevated in Sscby using a retroviral vector to transfect antisense for icIRAP into SSc cells. The cells will then be stimulated with TNF and PMA to determine if collagenase responsiveness is recovered (or possibly exaggerated). The mRNA for collagenase and the collagenase protein synthesized will be correlated with the amounts of icIRAP protein. Modeling of observed effects in SSc collagenase pathways will be done using normal fibroblasts transfected with retrovirus containing cDNA for icIRAP or stimulated with peptide fragments of icIRAP. The experiments should provide information for the control of collagenase expression in this disease as well as to provide information for the association of icIRAP with collagenase inhibition.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center (P50)
Project #
1P50AR044890-01A2
Application #
6553199
Study Section
Special Emphasis Panel (ZAR1)
Project Start
2001-08-24
Project End
2006-07-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Type
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Yin, Zhaohong; Carbone, Laura D; Gotoh, Mari et al. (2010) Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts. Rheumatology (Oxford) 49:2290-7
Postlethwaite, Arnold E; Harris, L Jeff; Raza, Syed H et al. (2010) Pharmacotherapy of systemic sclerosis. Expert Opin Pharmacother 11:789-806
Atamas, S P; Luzina, I G; Ingels, J et al. (2010) Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma). Clin Exp Immunol 161:426-35
Chiang, Thomas M; Postlethwaite, Arnold E (2008) Alteration in protein kinase B (AKT) activity in platelets from patients with systemic sclerosis. Thromb Res 122:501-6
Postlethwaite, Arnold E; Wong, Weng Kee; Clements, Philip et al. (2008) A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase di Arthritis Rheum 58:1810-22
Chiang, Thomas M; Postlethwaite, Arnold E (2007) A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis. Biochim Biophys Acta 1770:1181-6
Du, Haiming; Zawaski, Janice A; Gaber, M Waleed et al. (2007) A recombinant protein and a chemically synthesized peptide containing the active peptides of the platelet collagen receptors inhibit ferric chloride-induced thrombosis in a rat model. Thromb Res 121:419-26
Postlethwaite, Arnold E; Chiang, Thomas M (2007) Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 19:574-9
Zhu, Jiaqian; Cole, Flecia; Woo-Rasberry, Virginia et al. (2007) Type I and type III collagen-platelet interaction: inhibition by type specific receptor peptides. Thromb Res 119:111-9
Warrington, Kenneth J; Nair, Usha; Carbone, Laura D et al. (2006) Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res Ther 8:R136

Showing the most recent 10 out of 16 publications